Randomized, Double-blind Safety and Efficacy Study of Lis... | NCT00763971

NCT00763971

ID	Type	Description	Link
2008-000679-90	EudraCT Number

Status Module

Sponsor/Collaborators Module

Oversight Module

No data available

No data is available for this block.

Description Module

Conditions Module

Design Module

Interventional Study Design

Biospecimen

No data available

No data is available for this block.

Arms/Interventions Module

Arm Groups

Label	Type	Description	Intervention Names
Lisdexamfetamine Dimesylate (LDX)	Experimental	Overencapsulated LDX 30, 50, or 70mg	Drug: Lisdexamfetamine Dimesylate (LDX)
Methylphenidate Hydrochloride	Active Comparator	Overencapsulated Concerta 18, 36, or 54mg	Drug: Methylphenidate Hydrochloride
Placebo	Placebo Comparator	Overencapsulated Placebo	Drug: Placebo

Name	Type	Description	Arm Group Labels	Other Names
Lisdexamfetamine Dimesylate (LDX)	Drug	30, 50 or 70mg capsule once per day (Overencapsulated)	Lisdexamfetamine Dimesylate (LDX)

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
Change From Baseline in Attention Deficit Hyperactivity Disorder Rating Scale-fourth Edition (ADHD-RS-IV) Total Score at up to 7 Weeks	The ADHD-RS-IV consists of 18 items scored on a 4-point scale ranging from 0 (no symptoms) to 3 (severe symptoms) with total score ranging from 0 to 54. A decrease in score indicates an improvement in ADHD symptomology.	Baseline and up to 7 weeks

Secondary Outcomes

Measure	Description	Time Frame
Percentage of Participants With Improvement on Clinical Global Impression-Improvement (CGI-I) Scores	Clinical Global Impression-Improvement (CGI-I) consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved) or 2 (much improved) on the scale.	Up to 7 weeks

Eligibility Module

Eligibility Criteria

Inclusion Criteria:

Subject is a male or female aged 6-17 years inclusive at the time of consent.
Subject must meet Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition - Text Revision (DSM-IV-TR) criteria for a primary diagnosis of ADHD based on a detailed psychiatric evaluation.
Subject must have a Baseline ADHD-RS-IV total score ≥28.
Subject has blood pressure measurements within the 95th percentile for age, gender, and height at Screening and Baseline.
Subject is able to swallow a capsule.

Exclusion Criteria:

Subject has failed to respond to more than one adequate course (dose and duration) of stimulant therapy. One course must have been a long-acting formulation.
Subject has a conduct disorder. Oppositional Defiant Disorder is not exclusionary.
Subject is currently considered a suicide risk, has previously made a suicide attempt or has a prior history of, or is currently, demonstrating active suicidal ideation.
Subject has glaucoma.
Subject weighs less than 22.7kg (50lbs).
Subject is significantly overweight based on Centre for Disease Control and Prevention Body Mass Index (BMI)-for-age gender specific charts at Screening. Significantly overweight is defined as a BMI >97th percentile for this study.
Subject has a documented allergy, hypersensitivity, or intolerance to amphetamine or methylphenidate.
Subject has a documented allergy, hypersensitivity, or intolerance to any excipients in the test or reference products.
Subject has a history of seizures (other than infantile febrile seizures), a tic disorder, or a current diagnosis and/or a known family history of Tourette's Disorder.
Subject has a known history of symptomatic cardiovascular disease, advance arteriosclerosis, structural cardiac abnormality, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, or other serious cardiac problems that may place them at increased vulnerability to the sympathomimetic effects of a stimulant drug.
Subject has a known family history of sudden cardiac death or ventricular arrhythmia.
Subject is well controlled on their current ADHD medication with acceptable tolerability.
Subject has a pre-existing severe gastrointestinal tract narrowing (pathologic or iatrogenic).

Contacts/Locations Module

Name	Affiliation	Role
Study Director	Takeda	Study Director

Facility	Status	City	State	ZIP	Country	Contacts
ZiekenhuisNetwerk Antwerpen, Commandant Weynsstraat 165, Campus Hoge Beuken		Hoboken	Antwerp	2660	Belgium

References Module

Citations

PubMed Identifier	Type	Citation	Retractions
23332456	Result	Coghill D, Banaschewski T, Lecendreux M, Soutullo C, Johnson M, Zuddas A, Anderson C, Civil R, Higgins N, Lyne A, Squires L. European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder. Eur Neuropsychopharmacol. 2013 Oct;23(10):1208-18. doi: 10.1016/j.euroneuro.2012.11.012. Epub 2013 Jan 15.
23708466

Label	URL
FDA recal information	View source

IPD Sharing Statement Module

No data available

No data is available for this block.

Results Section

Participant Flow Module

Arm/Group Information

ID	Title	Description
FG000	Lisdexamfetamine Dimesylate (LDX)	Lisdexamfetamine Dimesylate (LDX, Vyvanse®, SPD489) was administered orally once-daily at approximately 7:00AM for 7 weeks (4-week dose optimization period and a 3-week dose maintenance period) at doses of either 30, 50, or 70 mg.
FG001	Methylphenidate Hydrochloride

Baseline Characteristics Module

Outcome Measures Module

Adverse Events Module

More Info Module

Annotation Section

No data available

No data is available for this block.

Document Section

No data available

No data is available for this block.

Derived Section

Miscellaneous Info Module

Submission Tracking

No data available

No data is available for this block.

Condition Browse Module

Intervention Browse Module

Masking Info

Type of Units Analyzed

Arm/Group Information

ID	Title	Description
BG000	Lisdexamfetamine Dimesylate (LDX)	Lisdexamfetamine Dimesylate (LDX, Vyvanse®, SPD489) was administered orally once-daily at approximately 7:00AM for 7 weeks (4-week dose optimization period and a 3-week dose maintenance period) at doses of either 30, 50, or 70 mg.
BG001	Methylphenidate Hydrochloride	Methylphenidate Hydrochloride (Concerta®, OROS MPH) was administered orally once-daily at approximately 7:00AM for 7 weeks (4-week dose optimization period and a 3-week dose maintenance period) at doses of either 18, 36, or 54 mg.
BG002	Placebo	Placebo was administered orally once-daily at approximately 7:00AM for 7 weeks.
BG003	Total	Total of all reporting groups

Baseline Measures

Title

Description

Population Description

Parameter Type

Dispersion Type

Unit of Measure

Calculate Percentage

Denominator Units Selected

Denominators

Classes

Age, Continuous

Safety Population was used for demographics. Safety Population defined as all subjects who took at least 1 dose of investigational product. Four randomized subjects (2 in the LDX group, 1 in the Methylphenidate group, and 1 in the placebo group) did not receive investigational product and were therefore excluded from the Safety Population (n = 332).

Mean

Standard Deviation

years

Title

Denominators

Categories

Title	Measurements
	BG00010.9± 2.87 BG00110.9± 2.63 BG00211.0± 2.82 BG003

Age, Customized

Count of Participants

Participants

Title

Denominators

Categories

6-12 years

Title	Measurements
	BG00077 BG001

Sex: Female, Male

Count of Participants

Participants

Title

Denominators

Categories

Title	Measurements
Female	BG00024 BG001

Region of Enrollment

This includes All Enrolled Subjects. Enrolled Population defined as all subjects who were randomized (n = 336).

Count of Participants

Participants

Title

Denominators

Categories

France

Title	Measurements
	BG00010 BG0019

Type

Title

Description

Population Description

Reporting Status

Anticipated Posting Date

Parameter Type

Dispersion Type

Unit of Measure

Calculate Percentage

Time Frame

Units Analyzed

Denominator Units Selected

Arm/Group Information

Denominators

Classes

Analyses

Primary

Change From Baseline in Attention Deficit Hyperactivity Disorder Rating Scale-fourth Edition (ADHD-RS-IV) Total Score at up to 7 Weeks

The ADHD-RS-IV consists of 18 items scored on a 4-point scale ranging from 0 (no symptoms) to 3 (severe symptoms) with total score ranging from 0 to 54. A decrease in score indicates an improvement in ADHD symptomology.

Full Analysis set (FAS) defined as all subjects who were randomized and who took at least 1 dose of investigational product.

Posted

Least Squares Mean

Standard Error

Scores on a scale

Baseline and up to 7 weeks

ID	Title	Description
OG000	Lisdexamfetamine Dimesylate (LDX)	Lisdexamfetamine Dimesylate (LDX, Vyvanse®, SPD489) was administered orally once-daily at approximately 7:00AM for 7 weeks (4-week dose optimization period and a 3-week dose maintenance period) at doses of either 30, 50, or 70 mg.
OG001	Methylphenidate Hydrochloride	Methylphenidate Hydrochloride (Concerta®, OROS MPH) was administered orally once-daily at approximately 7:00AM for 7 weeks (4-week dose optimization period and a 3-week dose maintenance period) at doses of either 18, 36, or 54 mg.
OG002	Placebo	Placebo was administered orally once-daily at approximately 7:00AM for 7 weeks.

Units	Counts
Participants	OG00098 OG001103 OG002104

Title

Denominators

Categories

Title	Measurements
	OG000-24.3± 1.16 OG001-18.7± 1.14 OG002-5.7± 1.13

Group IDs	Group Description	Statistical Method	Statistical Comment	P-Value	P-Value Comment	Parameter Type	Parameter Value	Dispersion Type	Dispersion Value	Confidence Interval Sides	Confidence Interval %	CI Lower Limit	CI Upper Limit	CI Lower Limit Comment	CI Upper Limit Comment	Estimate Comment	Tested Non-Inferiority	Non-Inferiority Type	Non-Inferiority Comment	Other Analysis Description
OG000 OG002		ANCOVA		<0.001		difference in LS means	-18.6			2-Sided	95	-21.5	-15.7					Superiority or Other (legacy)
OG001 OG002		ANCOVA		<0.001

Secondary

Percentage of Participants With Improvement on Clinical Global Impression-Improvement (CGI-I) Scores

Clinical Global Impression-Improvement (CGI-I) consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved) or 2 (much improved) on the scale.

FAS

Posted

Number

percentage of participants

Up to 7 weeks

ID	Title	Description
OG000	Lisdexamfetamine Dimesylate (LDX)	Lisdexamfetamine Dimesylate (LDX, Vyvanse®, SPD489) was administered orally once-daily at approximately 7:00AM for 7 weeks (4-week dose optimization period and a 3-week dose maintenance period) at doses of either 30, 50, or 70 mg.
OG001	Methylphenidate Hydrochloride	Methylphenidate Hydrochloride (Concerta®, OROS MPH) was administered orally once-daily at approximately 7:00AM for 7 weeks (4-week dose optimization period and a 3-week dose maintenance period) at doses of either 18, 36, or 54 mg.
OG002	Placebo	Placebo was administered orally once-daily at approximately 7:00AM for 7 weeks.

Secondary

Change From Baseline in Conner's Parent Rating Scale - Revised (CPRS-R) Total Score at up to 7 Weeks

The Conner's Parent rating Scale-revised short version (CPRS-R) consists of 27 questions graded on a scale from 0 (not true at all) to 3 (very much true) with a total score ranging from 0 to 81. Higher scores are indicative of increased ADHD. This scale allows parents to respond on the basis of the child's behavior and help assess ADHD and evaluate problem behavior.

FAS

Posted

Least Squares Mean

Standard Error

Scores on a scale

Baseline and up to 7 weeks

ID	Title	Description
OG000	Lisdexamfetamine Dimesylate (LDX)	Lisdexamfetamine Dimesylate (LDX, Vyvanse®, SPD489) was administered orally once-daily at approximately 7:00AM for 7 weeks (4-week dose optimization period and a 3-week dose maintenance period) at doses of either 30, 50, or 70 mg.
OG001	Methylphenidate Hydrochloride	Methylphenidate Hydrochloride (Concerta®, OROS MPH) was administered orally once-daily at approximately 7:00AM for 7 weeks (4-week dose optimization period and a 3-week dose maintenance period) at doses of either 18, 36, or 54 mg.
OG002	Placebo	Placebo was administered orally once-daily at approximately 7:00AM for 7 weeks.

Secondary

Health Utilities Index-2 (HUI-2) Scores at up to 7 Weeks

HUI is used to describe health status and to obtain utility scores by collecting data using one or more questionnaires in formats selected to match the specific study design criteria. Scoring ranges from 0.00 (dead) to 1.00 (perfect health). Higher scores represent better health status.

FAS

Posted

Mean

Standard Deviation

Scores on a scale

Baseline and up to 7 weeks

ID	Title	Description
OG000	Lisdexamfetamine Dimesylate (LDX)	Lisdexamfetamine Dimesylate (LDX, Vyvanse®, SPD489) was administered orally once-daily at approximately 7:00AM for 7 weeks (4-week dose optimization period and a 3-week dose maintenance period) at doses of either 30, 50, or 70 mg.
OG001	Methylphenidate Hydrochloride	Methylphenidate Hydrochloride (Concerta®, OROS MPH) was administered orally once-daily at approximately 7:00AM for 7 weeks (4-week dose optimization period and a 3-week dose maintenance period) at doses of either 18, 36, or 54 mg.
OG002	Placebo	Placebo was administered orally once-daily at approximately 7:00AM for 7 weeks.

Secondary

Change From Baseline in the Child Health and Illness Profile, Child Edition: Parent Report Form (CHIP-CE:PRF) Global T-score at up to 7 Weeks

The CHIP-CE:PRF evaluates health-related quality of life. It is composed of 5 domains (satisfaction, comfort, resilience, avoidance, and achievement) consisting of a total of 76 items. The global score is an average of the scores for the 5 domains. The majority of items assess frequency of events using a 5-point response format. There is no range for a total score. Raw scale scores are used to generate T-scores. Higher scores indicate better health.

FAS

Posted

Least Squares Mean

Standard Error

T-scores

Baseline and up to 7 weeks

ID	Title	Description
OG000	Lisdexamfetamine Dimesylate (LDX)	Lisdexamfetamine Dimesylate (LDX, Vyvanse®, SPD489) was administered orally once-daily at approximately 7:00AM for 7 weeks (4-week dose optimization period and a 3-week dose maintenance period) at doses of either 30, 50, or 70 mg.
OG001	Methylphenidate Hydrochloride	Methylphenidate Hydrochloride (Concerta®, OROS MPH) was administered orally once-daily at approximately 7:00AM for 7 weeks (4-week dose optimization period and a 3-week dose maintenance period) at doses of either 18, 36, or 54 mg.
OG002	Placebo

Secondary

Change From Baseline in Weiss Functional Impairment Rating Scale - Parent Report (WFIRS-P) Global Score at up to 7 Weeks

The WFIRS-P is a 50-item scale with each item scored from 0 (never/not at all) to 3 (very often/very much). Mean scores range from 0 to 3. Higher scores indicate greater functional impairment.

FAS

Posted

Least Squares Mean

Standard Error

Scores on a scale

Baseline and up to 7 weeks

ID	Title	Description
OG000	Lisdexamfetamine Dimesylate (LDX)	Lisdexamfetamine Dimesylate (LDX, Vyvanse®, SPD489) was administered orally once-daily at approximately 7:00AM for 7 weeks (4-week dose optimization period and a 3-week dose maintenance period) at doses of either 30, 50, or 70 mg.
OG001	Methylphenidate Hydrochloride	Methylphenidate Hydrochloride (Concerta®, OROS MPH) was administered orally once-daily at approximately 7:00AM for 7 weeks (4-week dose optimization period and a 3-week dose maintenance period) at doses of either 18, 36, or 54 mg.
OG002	Placebo	Placebo was administered orally once-daily at approximately 7:00AM for 7 weeks.

Secondary

Change From Baseline in Brief Psychiatric Rating Scale for Children (BPRS-C) Total Score at up to 7 Weeks

The BPRS-C characterizes psychopathology. A total of 21 items are rated on a scale from 0 (not present) to 6 (extremely severe) with a total score ranging from 0 to 126. A decrease in score indicates a reduction in psychopathology.

Safety Population defined as all subjects who took at least 1 dose of investigational product.

Posted

Mean

Standard Deviation

Scores on a scale

Baseline and up to 7 weeks

ID	Title	Description
OG000	Lisdexamfetamine Dimesylate (LDX)	Lisdexamfetamine Dimesylate (LDX, Vyvanse®, SPD489) was administered orally once-daily at approximately 7:00AM for 7 weeks (4-week dose optimization period and a 3-week dose maintenance period) at doses of either 30, 50, or 70 mg.
OG001	Methylphenidate Hydrochloride	Methylphenidate Hydrochloride (Concerta®, OROS MPH) was administered orally once-daily at approximately 7:00AM for 7 weeks (4-week dose optimization period and a 3-week dose maintenance period) at doses of either 18, 36, or 54 mg.
OG002	Placebo	Placebo was administered orally once-daily at approximately 7:00AM for 7 weeks.

Secondary

Columbia-Suicide Severity Rating Scale (C-SSRS)

C-SSRS is a 19-item semi-structured interview designed to capture suicide-related thoughts and behaviors.

Safety Population

Posted

Number

participants

Up to 7 weeks

ID	Title	Description
OG000	Lisdexamfetamine Dimesylate (LDX)	Lisdexamfetamine Dimesylate (LDX, Vyvanse®, SPD489) was administered orally once-daily at approximately 7:00AM for 7 weeks (4-week dose optimization period and a 3-week dose maintenance period) at doses of either 30, 50, or 70 mg.
OG001	Methylphenidate Hydrochloride	Methylphenidate Hydrochloride (Concerta®, OROS MPH) was administered orally once-daily at approximately 7:00AM for 7 weeks (4-week dose optimization period and a 3-week dose maintenance period) at doses of either 18, 36, or 54 mg.
OG002	Placebo	Placebo was administered orally once-daily at approximately 7:00AM for 7 weeks.

Units	Counts

Arm/Groups

ID	Title	Description	Serious Events (Affected)	Serious Events (At Risk)	Other Events (Affected)	Other Events (At Risk)
EG000	Lisdexamfetamine Dimesylate (LDX)	Lisdexamfetamine Dimesylate (LDX, Vyvanse®, SPD489) was administered orally once-daily at approximately 7:00AM for 7 weeks (4-week dose optimization period and a 3-week dose maintenance period) at doses of either 30, 50, or 70 mg.	3	111	80	111
EG001	Methylphenidate Hydrochloride	Methylphenidate Hydrochloride (Concerta®, OROS MPH) was administered orally once-daily at approximately 7:00AM for 7 weeks (4-week dose optimization period and a 3-week dose maintenance period) at doses of either 18, 36, or 54 mg.	2	111	72	111
EG002	Placebo	Placebo was administered orally once-daily at approximately 7:00AM for 7 weeks.	3	110	63	110

Serious Adverse Events

Term	Organ System	Statistical Information
Syncope	Nervous system disorders	EG0001 affected111 at risk EG0011 affected111 at risk EG0020 affected110 at risk
Gastroesophageal reflux disease	Gastrointestinal disorders	EG0001 affected111 at risk EG0010 affected111 at risk EG0020 affected110 at risk
Appendicitis	Infections and infestations	EG0001 affected111 at risk EG0010 affected111 at risk EG0020 affected110 at risk
Loss of conciousness	Nervous system disorders	EG0000 affected111 at risk EG0010 affected111 at risk EG0021 affected110 at risk
Hematoma	Vascular disorders	EG0000 affected111 at risk EG0010 affected111 at risk EG0021 affected110 at risk
Clavicle fracture	Injury, poisoning and procedural complications	EG0000 affected111 at risk EG0010 affected111 at risk EG0021 affected110 at risk
Overdose	Injury, poisoning and procedural complications	EG0000 affected111 at risk EG0011 affected111 at risk EG0020 affected110 at risk

Other Adverse Events

Term	Organ System	Statistical Information
Abdominal pain	Gastrointestinal disorders	EG0006 events6 affected111 at risk EG0014 events4 affected111 at risk EG00210 events6 affected110 at risk
Abdominal upper pain	Gastrointestinal disorders	EG00015 events8 affected111 at risk EG00110 events9 affected111 at risk EG0029 events6 affected110 at risk
Diarrhea	Gastrointestinal disorders	EG0008 events5 affected111 at risk EG0012 events2 affected111 at risk EG0023 events3 affected110 at risk
Nausea	Gastrointestinal disorders	EG00014 events12 affected111 at risk EG0018 events8 affected111 at risk EG0024 events3 affected110 at risk
Vomiting	Gastrointestinal disorders	EG0005 events4 affected111 at risk EG0014 events4 affected111 at risk EG0021 events1 affected110 at risk
Fatigue	General disorders	EG0005 events5 affected111 at risk EG0011 events1 affected111 at risk EG0023 events3 affected110 at risk
Irritability	General disorders	EG0006 events4 affected111 at risk EG0015 events4 affected111 at risk EG0020 events0 affected110 at risk
Pyrexia	General disorders	EG0003 events3 affected111 at risk EG0015 events5 affected111 at risk EG0020 events0 affected110 at risk
Gastroenteritis	Infections and infestations	EG0004 events4 affected111 at risk EG0013 events3 affected111 at risk EG0021 events1 affected110 at risk
Influenza	Infections and infestations	EG0000 events0 affected111 at risk EG0013 events3 affected111 at risk EG0020 events0 affected110 at risk
Nasopharyngitis	Infections and infestations	EG0009 events8 affected111 at risk EG00114 events14 affected111 at risk EG0029 events8 affected110 at risk
Upper respiratory tract infection	Infections and infestations	EG0003 events3 affected111 at risk EG0011 events1 affected111 at risk EG0022 events2 affected110 at risk
Joint sprain	Injury, poisoning and procedural complications	EG0000 events0 affected111 at risk EG0014 events4 affected111 at risk EG0021 events1 affected110 at risk
Wrong drug administered	Injury, poisoning and procedural complications	EG0004 events4 affected111 at risk EG0012 events2 affected111 at risk EG0021 events1 affected110 at risk
Electrocardiogram QT prolonged	Investigations	EG0007 events3 affected111 at risk EG0011 events1 affected111 at risk EG0021 events1 affected110 at risk
Weight decreased	Investigations	EG00015 events15 affected111 at risk EG0015 events5 affected111 at risk EG0020 events0 affected110 at risk
Anorexia	Metabolism and nutrition disorders	EG00013 events12 affected111 at risk EG0018 events6 affected111 at risk EG0022 events2 affected110 at risk
Decreased appetite	Metabolism and nutrition disorders	EG00031 events28 affected111 at risk EG00121 events17 affected111 at risk EG0023 events3 affected110 at risk
Dizziness	Nervous system disorders	EG0004 events4 affected111 at risk EG0012 events2 affected111 at risk EG0021 events1 affected110 at risk
Headache	Nervous system disorders	EG00021 events16 affected111 at risk EG00130 events22 affected111 at risk EG00227 events22 affected110 at risk
Migraine	Nervous system disorders	EG0004 events3 affected111 at risk EG0011 events1 affected111 at risk EG0020 events0 affected110 at risk
Aggression	Psychiatric disorders	EG0004 events4 affected111 at risk EG0013 events3 affected111 at risk EG0021 events1 affected110 at risk
Initial insomnia	Psychiatric disorders	EG0003 events3 affected111 at risk EG0017 events7 affected111 at risk EG0021 events1 affected110 at risk
Insomnia	Psychiatric disorders	EG00016 events16 affected111 at risk EG0019 events9 affected111 at risk EG0020 events0 affected110 at risk
Sleep disorder	Psychiatric disorders	EG0006 events6 affected111 at risk EG0012 events2 affected111 at risk EG0021 events1 affected110 at risk
Tic	Psychiatric disorders	EG0002 events2 affected111 at risk EG0014 events3 affected111 at risk EG0022 events2 affected110 at risk
Cough	Respiratory, thoracic and mediastinal disorders	EG0003 events3 affected111 at risk EG0018 events8 affected111 at risk EG0020 events0 affected110 at risk
Erythema	Skin and subcutaneous tissue disorders	EG0001 events1 affected111 at risk EG0010 events0 affected111 at risk EG0024 events3 affected110 at risk

ID	Term
D001289	Attention Deficit Disorder with Hyperactivity

ID	Term
D000069478	Lisdexamfetamine Dimesylate
D008774	Methylphenidate

Ancestor Terms

ID	Term
D003913	Dextroamphetamine
D000661	Amphetamine
D000662	Amphetamines
D010627	Phenethylamines
D005021	Ethylamines
D000588	Amines
D009930	Organic Chemicals
D010648	Phenylacetates
D000146	Acids, Carbocyclic
D002264	Carboxylic Acids
D010880	Piperidines
D006573	Heterocyclic Compounds, 1-Ring
D006571	Heterocyclic Compounds

Units	Counts
Participants	OG000100 OG001104 OG002104

Units	Counts
Participants	OG00098 OG001103 OG00297

Units	Counts
Participants	OG00079 OG00183 OG00287

ID	Term
D019958	Attention Deficit and Disruptive Behavior Disorders
D065886	Neurodevelopmental Disorders
D001523	Mental Disorders